May 16, 2023
Dermavant Reports Positive Topline Results from AD ...
Read More
March 15, 2023
Dermavant Reports Positive Topline Results from AD ...
Read More
March 10, 2023
Dermavant to Present Data from Multiple Studies of ...
Read More
February 13, 2023
Dermavant Completes Enrollment of Two Phase 3 Clin ...
Read More
January 12, 2023
Dermavant to Present Data from Multiple Studies of ...
Read More
October 13, 2022
Dermavant to Present Data from Multiple Clinical T ...
Read More
March 25, 2022
Dermavant Showcases New Long-Term Durability and T ...
Read More
March 11, 2022
Dermavant to Present New Data from the Phase 3 PSO ...
Read More
March 8, 2022
Dermavant Appoints Nancy Beesley to its Board of D ...
Read More
January 15, 2022
Dermavant Presents New Patient Satisfaction Data f ...
Read More
January 7, 2022
Dermavant to Present New Data from Phase 3 PSOARIN ...
Read More
December 9, 2021
Dermavant Announces Publication of PSOARING 1 ...
Read More
December 9, 2021
The New England Journal of Medicine: Phase 3 Trial ...
Read More
September 30, 2021
Dermavant Showcases New Long-Term Data from Phase ...
Read More
September 23, 2021
Dermavant to Present New Data on Phase 3 PSOARING ...
Read More
September 9, 2021
Dermavant Announces First Patient Dosed in ADORING ...
Read More
August 10, 2021
Dermavant Announces FDA Acceptance for Filing of N ...
Read More
June 7, 2021
Dermavant Announces $200 Million of Financing ...
Read More
June 3, 2021
Dermavant Submits New Drug Application (NDA) to FD ...
Read More
May 6, 2021
Dermavant Announces Appointment of Michael Swartzb ...
Read More
